A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Anthropodermic bibliopegy—the binding of books in human skin—peaked in the 19th century. The practice was most popular amongst doctors, who had access to cadavers in their profession. It was nonetheless a rare phenomenon even at the peak of its popularity, and fraudulent claims were commonplace; by 2020, the Anthropodermic Book Project had confirmed the existence of 18 books bound in human skin, out of 31 tested cases. The ability to unequivocally identify book bindings as being of human skin dates only to the mid-2010s. For many years, identification tended to be visual, based predominantly on the structure of pores such as hair follicles in the skin. This could be combined with evidence as circumstantial as the bindings being of subjectively poor quality—taken as a sign the skin used was acquired through suspicious means. In the early twenty-first century, DNA testing emerged as a potential means of identification, but this was confounded by human handling; items frequently touched by human hands could produce false positives, as tests would pick up on their remnants. DNA testing also proved non-viable owing to the degradation of DNA over time and the acceleration of such degradation by the tanning process used to turn skin into leather. The development of peptide mass fingerprinting permitted conclusive testing and became the gold standard method. The first book confirmed as authentic through its use was in 2014; it was a copy of Des destinées de l'ame by the French philosopher Arsène Houssaye, held in the Houghton Library of Harvard University.
== History of electric slow cookers == Slow cookers achieved popularity in the United States during the 1940s, when many women began to work outside the home. They could start dinner cooking in the morning before going to work and finish preparing the meal in the evening when they came home. The Naxon Utilities Corporation of Chicago, under the leadership of electrical engineer Irving Naxon (born Irving Nachumsohn), developed the Naxon Beanery All-Purpose Cooker for the purposes of cooking a bean meal. Naxon was inspired by a story related by his mother, how in her native Lithuanian town his grandmother made a traditional Jewish stew called cholent, which took several hours to cook in an oven. A 1950 advertisement shows a slow cooker called the "Simmer Crock" made by the Industrial Radiant Heat Corporation of Gladstone, New Jersey. The Rival Company of Kansas City, Missouri, bought Naxon in 1970, acquiring Naxon's 1940 patent for the bean simmer cooker. Rival asked inventor Alex MacMaster, from Boonville, Missouri, to develop Naxon's bean cooker into a large scale production model that could cook an entire family meal, going further than just cooking a bean meal. Alex also designed and produced the mass-production machines for Rival's manufacturing line of the Crock-Pot. The cooker was then reintroduced under the trademark "Crock-Pot" in 1971. In 1974, Rival introduced removable stoneware inserts, making the appliance easier to clean. As of 2016, the Crock-Pot brand belongs to Newell Brands.
=== Other enterprises === C.P. Company, an Italian apparel brand Cedar Point, an amusement park in Sandusky, Ohio, US Central Partnership, a Russian film distributor and production company Charoen Pokphand (C.P. Group), a Thai agribusiness conglomerate Chicago Pneumatic, an American manufacturer of tools and equipment Colgate-Palmolive, an American consumer goods company Commercial Press, a Chinese publishing company Connaught Place, New Delhi, a commercial centre in India Curious Pastimes, a UK-based gaming company
== Awards == Borden Award (American Chemical Society) 1957 Bond Award (American Oil Chemists’ Society) 1973 Agricultural and Food Chemistry Award (American Chemical Society) 1973 Senior Scientist Award (Alexander von Humboldt Foundation) 1981 Macy-Gyorgy Award for Research in Human Milk and Lactation 1997 Penn State Alumni Fellow Award 2001 Penn State Distinguished Alumnus Award 2002
=== Appearance === Walls of Tarlov cysts are thin and fibrous; they are prone to rupture if touched, making surgery difficult. The nerve fibers embedded in the walls of the cysts have the appearance and size of dental floss; these nerve fibers are usually not arranged in any specific alignment. Histologic examination reveals the Tarlov-cyst outer wall is composed of vascular connective tissue, and the inner wall is lined with flattened arachnoid tissue. In addition, part of the lining containing nerve fibers also occasionally contains ganglion cells. The cysts can contain anywhere from a couple of milliliters of CSF to over 2.5 litres (0.5 imp gal; 0.7 US gal) of CSF.
Sources: en.wikipedia.org
The picture is elaborately framed by five successive decorative borders with naturalistic vine rinceau, suggestive of Roman art. The colors of the murals are various shades of brown, with smatterings of light green, but no blue, defining the so-called "orange and green" style. The center of the ceiling has motifs of the sun and moon, two monks, and a bird flying with a human figure in its claws. The sides of the ceiling are composed of diamond-shaped mountains, around which are naturalistic motifs of humans, animals, lakes and trees, a possibly Near-Eastern design which was generally adopted in later caves at Kizil. A band of fantastic animals separated the ceiling from the side walls. The general style appears to be early, and possibly derived from Kashmir and Cave 24 at Bamiyan. The lunettes bordering the ceiling display ornate Buddhist scenes. The right lunette is difficult to identify, but seems to represent a king or a Bodhisattava bending towards a warrior figure. The bottom portion shows a palatial scene, with a figure on a couch surrounded by devatas. The left lunette shows the Buddha of the future Maitreya in the Tusita Heaven. Below this is a depiction of Mount Sumeru surrounding by various Nagas, figures of devotees, and animals. Small figures of kneeling devotees in tunics, about 40 centimeters (15 inches) tall, some armed with a dagger, appear next to the left and right corners of the back-wall mural: probably noble and wealthy Kuchean donors of the 4th century CE. One of the donors holds three burning incense cones.
Alloxan is a toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is, beta cells) when administered to rodents and many other animal species. This causes an insulin-dependent diabetes mellitus (called "alloxan diabetes") in these animals, with characteristics similar to type 1 diabetes in humans. Alloxan is selectively toxic to insulin-producing pancreatic beta cells because it preferentially accumulates in beta cells through uptake via the GLUT2 glucose transporter. Studies suggest alloxan does not cause diabetes in humans. Others found a significant difference in alloxan plasma levels in children with and without type 1 diabetes. Alloxan (C4H2N2O4) readily undergoes redox cycling with its one-electron (C4H3N2O4• semiquinone) and two-electron (dialuric acid, C4H4N2O4) reduction products. In the presence of intracellular reductants such as glutathione (or other thiols), this leads to the generation of toxic reactive oxygen species (ROS) via the interaction of alloxan reduction products with molecular oxygen and related species:
=== Okinawa, Japan === Between 1995 and 1996, U.S. Marine AV-8B Harrier jets accidentally fired more than 1,500 DU rounds at the Tori Shima gunnery range. The military did not notify the Japanese government until January 1997.
The relationship between pressure and volume was first noted by Richard Towneley and Henry Power in the 17th century. Robert Boyle confirmed their discovery through experiments and published the results. According to Robert Gunther and other authorities, it was Boyle's assistant, Robert Hooke, who built the experimental apparatus. Boyle's law is based on experiments with air, which he considered to be a fluid of particles at rest in between small invisible springs. Boyle may have begun experimenting with gases due to an interest in air as an essential element of life; for example, he published works on the growth of plants without air. Boyle used a closed J-shaped tube and after pouring mercury from one side he forced the air on the other side to contract under the pressure of mercury. After repeating the experiment several times and using different amounts of mercury he found that under controlled conditions, the pressure of a gas is inversely proportional to the volume occupied by it. The French physicist Edme Mariotte (1620–1684) discovered the same law independently of Boyle in 1679, after Boyle had published it in 1662. Mariotte did, however, discover that air volume changes with temperature. Thus this law is sometimes referred to as Mariotte's law or the Boyle–Mariotte law.
Sources: en.wikipedia.org
Petroleum in some form has been used since ancient times. More than 4,300 years ago, bitumen was mentioned when the Sumerians used it to make boats. A tablet of the legend of the birth of Sargon of Akkad mentions a basket which was closed by straw and bitumen. More than 4,000 years ago, according to Herodotus and Diodorus Siculus, asphalt (bitumen) was used in the construction of the walls and towers of Babylon; there were oil pits near Ardericca and Babylon and a pitch spring on Zakynthos. In Babylon, petroleum was used for road construction, ship caulking, and medicine. The use of petroleum in ancient China dates back more than 2,000 years. The I Ching, one of the earliest Chinese writings, cites that oil in its raw state, without refining, was first discovered, extracted, and used in China in the 1st century BCE. In addition, the Chinese were the first to record the use of petroleum as fuel as early as the 4th century BCE. By 347 CE, oil was produced from bamboo-drilled wells in China. In the 7th century, petroleum was among the essential ingredients for Greek fire, an incendiary projectile weapon that was used by Byzantine Greeks against Arab ships attacking Constantinople. Crude oil was distilled by Persian chemists, with clear descriptions given in Arabic handbooks such as those of Abu Bakr al-Razi. In the 9th century, oil fields were exploited in the area around modern Baku, Azerbaijan. These fields were described by Abu Bakr al-Razi in the 10th century and by Marco Polo in the 13th century, who describes the output of those wells as hundreds of shiploads.
=== Subcellular sequestration === On protein level, CK1δ activity can be regulated by sequestration to particular subcellular compartments bringing the kinase together with distinct pools of substrates in order to guide its cellular function. This sequestration is usually facilitated by scaffolding proteins, which are also supposed to allosterically control the activity of the interacting kinase. For CK1δ subcellular sequestration has been described to be mediated by A-kinase anchor protein (AKAP) 450, the X-linked DEAD-box RNA helicase 3 (DDX3X), casein kinase-1 binding protein (CK1BP), and the regulatory and complex-building/-initiating molecule 14-3-3 ζ. AKAP450 recruits CK1δ and ε to the centrosome to exert centrosome-specific functions in the context of cell cycle regulation. DDX3X promotes CK1ε-mediated phosphorylation of Dishevelled (Dvl) in the canonical Wnt pathway but has also been demonstrated to stimulate CK1δ- and ε-specific kinase activity by up to five orders of magnitude. On the contrary, proteins being homologous to CK1BP (e.g. dysbindin or BLOC-1 [biogenesis of lysosome-related organelles complex-1]) are able to inhibit CK1δ kinase activity in a dose dependent manner.
== WADA proscription == In 2015, Radwa Arafa Abd Elsalam, an athlete from Egypt, underwent a doping control where ractopamine was identified in the sample. Elsalam was sanctioned by the Egyptian Anti-Doping Organisation (EGY-NADO) with a two year ineligibility period for non-intentional presence of a prohibited substance, in violation of Article 2.1 of the EGY-NADO rules. While not mentioned by name in the 2015 Prohibited List, ractopamine was determined to — much like clenbuterol, another β2-adrenergic agonist — constitute an Other Anabolic Agent prohibited under S1.2. Elsalam appealed the decision, claiming that ractopamine is used in the meat industry overseas, so she must have inadvertently consumed food contaminated with ractopamine. EGY-NADO accepted her appeal, reduced the sanction to six months, and provided the World Anti-Doping Agency (WADA) with records pertaining to the case. WADA filed an appeal with the Court of Arbitration for Sport (CAS) against EGY-NADO and Elsalam with respect to the appealed decision. WADA asserted ractopamine was "undisputed[ly]" an Other Anabolic Agent, that "[i]t is not sufficient for an athlete merely to make protestations of innocence and suggest that the prohibited substance must have entered her body in inadvertently", and that "her explanations are nothing more than mere speculation".
Pipecolic acid (piperidine-2-carboxylic acid) is an organic compound with the formula HNC5H9CO2H. It is a carboxylic acid derivative of piperidine and, as such, an amino acid, although one not encoded genetically. Like many other α-amino acids, pipecolic acid is chiral, although the S-stereoisomer is more common. It is a colorless solid. Its biosynthesis starts from lysine. CRYM, a taxon-specific protein that also binds thyroid hormones, is involved in the pipecolic acid pathway.
In early 1902, British tactics of containment, denial, and harassment finally began to yield results against the Boer guerrillas. The sourcing and co-ordination of intelligence became increasingly efficient with regular reporting from observers in the blockhouses, from units patrolling the fences and conducting "sweeper" operations, and from native Africans in rural areas who increasingly supplied intelligence, as the Scorched Earth policy took effect and they found themselves competing with the Boers for food supplies. Kitchener's forces at last began to affect the Boers' fighting strength and freedom of manoeuvre, and made it harder for the Boers and their families to survive. Despite this success, almost half the Boer fighting strength, around 15,000 men, were still in the field fighting by May 1902. However, Kitchener's tactics were costly: Britain was running out of time, patience, and money needed for the war. The British offered terms of peace on various occasions, notably in March 1901, but all them were rejected by Botha and the "Bitter-enders" among the Boers, who pledged to fight until the bitter end and rejected the demand for surrender or any compromise made by the "Hands-uppers". Their reasons included their hatred of the British, loyalty to their dead comrades, solidarity with fellow Boer commandos, a desire for independence, religious arguments, and fear of captivity or punishment. On the other hand, their women and children were dying in prison camps every day, and independence seemed more and more impossible.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.